fda d.i.s.c.o. burst edition: fda approves tebentafusp-tebn for unresectable or metastatic uveal ...
Published 3 months ago • 16 plays • Length 4:01Download video MP4
Download video MP3
Similar videos
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of tabrecta (capmatinib) for metastatic non-small cel...
-
5:01
fda d.i.s.c.o. burst edition: fda approval of tafinlar (dabrafenib) in combination with mekinist ...
-
4:01
fda d.i.s.c.o. burst edition: fda approval of tafinlar (dabrafenib) with mekinist (trametinib) fo...
-
4:01
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) in combination with azacitidin...
-
5:01
fda d.i.s.c.o. burst edition: fda approvals of tivdak (tisotumab vedotin-tftv) for recurrent or m...
-
3:01
fda d.i.s.c.o. burst edition: fda approval of keytruda (pembrolizumab) in combination with trastu...
-
3:01
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) for adult patients with previo...
-
4:01
fda d.i.s.c.o. burst edition: fda approval of tecentriq (atezolizumab) for adjuvant treatment fol...
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of verzenio (abemaciclib) for adjuvant treatment of a...
-
3:00
fda d.i.s.c.o. burst edition: fda approval of augtyro (repotrectinib) for locally advanced or met...
-
4:01
fda d.i.s.c.o. burst edition: lorbrena (lorlatinib) for patients with metastatic non-small cell l...
-
5:31
fda d.i.s.c.o. burst edition: fda approvals of trodelvy (sacituzumab govitecan) for locally advan...
-
4:01
fda d.i.s.c.o. burst edition: fda approval of retevmo (selpercatinib) for advanced or metastatic ...
-
4:31
fda d.i.s.c.o.: burst edition: fda approval of pluvicto (lutetium lu 177 vipivotide tetraxetan) f...
-
6:01
fda d.i.s.c.o. burst edition: fda approvals of imbruvica (ibrutinib) for pediatric patients with ...
-
3:31
fda d.i.s.c.o. burst edition: fda approval of pedmark (sodium thiosulfate) to reduce the risk of ...
-
4:01
fda d.i.s.c.o. burst edition: fda approves a new dosing regimen for asparaginase erwinia chrysant...
-
5:01
fda d.i.s.c.o. burst edition: fda approval of breyanzi (lisocabtagene maraleucel) for second-line...